JP2022530241A - Ｃｄｋ阻害剤と組み合わせたｒａｎｋ経路阻害剤 - Google Patents

Ｃｄｋ阻害剤と組み合わせたｒａｎｋ経路阻害剤 Download PDF

Info

Publication number
JP2022530241A
JP2022530241A JP2021564120A JP2021564120A JP2022530241A JP 2022530241 A JP2022530241 A JP 2022530241A JP 2021564120 A JP2021564120 A JP 2021564120A JP 2021564120 A JP2021564120 A JP 2021564120A JP 2022530241 A JP2022530241 A JP 2022530241A
Authority
JP
Japan
Prior art keywords
inhibitor
seq
rank
amino acid
acid sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2021564120A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022530241A5 (enExample
Inventor
コスタ， ルイス アントニオ マルケス ダ
アンジョ カシミロ， サンドラ クリスティナ カラ デ
Original Assignee
インスチトゥート デ メディシーナ モリクラール ジョアン ロボ アントゥネス
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by インスチトゥート デ メディシーナ モリクラール ジョアン ロボ アントゥネス filed Critical インスチトゥート デ メディシーナ モリクラール ジョアン ロボ アントゥネス
Publication of JP2022530241A publication Critical patent/JP2022530241A/ja
Publication of JP2022530241A5 publication Critical patent/JP2022530241A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2875—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Steroid Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Plural Heterocyclic Compounds (AREA)
JP2021564120A 2019-04-30 2020-04-24 Ｃｄｋ阻害剤と組み合わせたｒａｎｋ経路阻害剤 Pending JP2022530241A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201962840810P 2019-04-30 2019-04-30
US62/840,810 2019-04-30
PT115483 2019-04-30
PT11548319 2019-04-30
PCT/PT2020/050017 WO2020222668A1 (en) 2019-04-30 2020-04-24 Rank pathway inhibitors in combination with cdk inhibitors

Publications (2)

Publication Number Publication Date
JP2022530241A true JP2022530241A (ja) 2022-06-28
JP2022530241A5 JP2022530241A5 (enExample) 2023-05-08

Family

ID=70775461

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021564120A Pending JP2022530241A (ja) 2019-04-30 2020-04-24 Ｃｄｋ阻害剤と組み合わせたｒａｎｋ経路阻害剤

Country Status (9)

Country Link
US (1) US20220195059A1 (enExample)
EP (1) EP3962945A1 (enExample)
JP (1) JP2022530241A (enExample)
KR (1) KR20220002316A (enExample)
AU (1) AU2020266083A1 (enExample)
BR (1) BR112021021663A2 (enExample)
CA (1) CA3132656A1 (enExample)
MX (1) MX2021013271A (enExample)
WO (1) WO2020222668A1 (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20240254245A1 (en) * 2021-05-12 2024-08-01 Jiangsu Hengrui Pharmaceuticals Co., Ltd. Antigen binding molecule specifically binding to rankl and ngf, and medical use thereof
CN115369089A (zh) * 2022-08-11 2022-11-22 中山大学孙逸仙纪念医院 两种er阳性her-2阴性乳腺癌cdk4/6抑制剂耐药株及其构建方法和用途
CN115718192B (zh) * 2022-11-25 2025-02-14 浙江洛兮医疗科技有限公司 一种免疫组化即用型pd-l1抗体试剂
EP4626890A1 (en) 2022-12-01 2025-10-08 KRKA, d.d., Novo mesto Ribociclib salts and formulations thereof
CN117643591A (zh) * 2023-02-23 2024-03-05 四川大学华西医院 一种用于mycn扩增型rb的抑制剂及抑制效果验证方法

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US581916A (en) 1897-05-04 Harvester
US4450150A (en) 1973-05-17 1984-05-22 Arthur D. Little, Inc. Biodegradable, implantable drug delivery depots, and method for preparing and using the same
US4342776A (en) 1979-11-05 1982-08-03 Merck & Co., Inc. 4-Substituted-3-hydroxy-3-pyrroline-2,5-dione inhibitors of glycolic acid oxidase
US4399276A (en) 1981-01-09 1983-08-16 Kabushiki Kaisha Yakult Honsha 7-Substituted camptothecin derivatives
US4473692A (en) 1981-09-04 1984-09-25 Kabushiki Kaisha Yakult Honsha Camptothecin derivatives and process for preparing same
JPS5839685A (ja) 1981-09-04 1983-03-08 Yakult Honsha Co Ltd 新規なカンプトテシン誘導体及びその製造法
JPS58154582A (ja) 1982-03-10 1983-09-14 Yakult Honsha Co Ltd 新規なカンプトテシン誘導体およびその製造法
US4526988A (en) 1983-03-10 1985-07-02 Eli Lilly And Company Difluoro antivirals and intermediate therefor
JPS6019790A (ja) 1983-07-14 1985-01-31 Yakult Honsha Co Ltd 新規なカンプトテシン誘導体
DE3587500T2 (de) 1984-12-04 1993-12-16 Lilly Co Eli Tumorbehandlung bei Säugetieren.
US5223608A (en) 1987-08-28 1993-06-29 Eli Lilly And Company Process for and intermediates of 2',2'-difluoronucleosides
US5004758A (en) 1987-12-01 1991-04-02 Smithkline Beecham Corporation Water soluble camptothecin analogs useful for inhibiting the growth of animal tumor cells
ES2165346T3 (es) 1989-09-15 2002-03-16 Res Triangle Inst Analogos de 10,11-metilendioxi-20(rs)-camptotecina y 10,11-metilendioxi-20(s)-camptotecina.
FR2707988B1 (fr) 1993-07-21 1995-10-13 Pf Medicament Nouveaux dérivés antimitotiques des alcaloïdes binaires du catharantus rosesus, leur procédé de préparation et les compositions pharmaceutiques les comprenant.
WO1999040942A1 (en) 1998-02-10 1999-08-19 Yoshitomi Pharmaceutical Industries, Ltd. Preparations with controlled release
JP2003530297A (ja) 1998-10-16 2003-10-14 ザ ガバメント オブ ザ ユナイテッド ステイツ オブ アメリカ， リプリゼンテッド バイ ザ セクレタリー オブ ザ デパートメント オブ ヘルス アンド ヒューマン サービシーズ Ｖｉｐアンタゴニストを用いる併用療法
GB2344287A (en) 1998-12-03 2000-06-07 Ferring Bv Controlled release pharmaceutical formulation
WO2003033499A2 (en) 2001-10-15 2003-04-24 Gpc Biotech Inc. Inhibitors of cyclin-dependent kinases, compositions and uses related thereto
IL159120A0 (en) 2001-05-29 2004-05-12 Schering Ag Cdk inhibiting pyrimidines, production thereof and their use as medicaments
TR201809678T4 (tr) 2001-06-26 2018-07-23 Amgen Fremont Inc Opgl ye karşi antikorlar.
US7771951B2 (en) 2001-12-03 2010-08-10 Amgen Fremont Inc. Antibody categorization based on binding characteristics
NZ535232A (en) 2002-02-28 2007-05-31 Univ Temple Amino-substituted (E)-2,6-dialkoxystyryl 4-substituted benzylsulfones for treating proliferative disorders
US6818663B2 (en) 2002-05-17 2004-11-16 Hoffmann-La Roches Diaminothiazoles
WO2004033036A2 (en) 2002-10-04 2004-04-22 Microchips, Inc. Medical device for controlled drug delivery and cardiac monitoring and/or stimulation
WO2004069137A2 (de) 2003-02-07 2004-08-19 Ge Bayer Silicones Gmbh & Co. Kg Verwendung von polyamino- und/oder polyammonium-polysiloxancopolymeren
WO2004097048A1 (en) 2003-04-28 2004-11-11 Canon Kabushiki Kaisha Process for assay of nucleic acid by competitive hybridization using a dna microarray
WO2008130158A1 (en) 2007-04-19 2008-10-30 Dong-A Pharmaceutical. Co., Ltd A biodegradable microsphere composition suitable for the controlled release of glucose controlling peptide and formulation thereof
CA3025264A1 (en) * 2016-05-25 2017-11-30 Inbiomotion S.L. Therapeutic treatment of breast cancer based on c-maf status
EP3654967A4 (en) * 2017-07-21 2021-04-21 Eisai R&D Management Co., Ltd. USE OF EIBULIN AND CYCLINE-DEPENDENT KINASE INHIBITORS IN THE TREATMENT OF CANCER

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
BREAST CANCER RES. TREAT., vol. 166, JPN6024017219, 2017, pages 41 - 54, ISSN: 0005470940 *
CANCER MEDICINE, vol. 3, no. 5, JPN6024017218, 2014, pages 1112 - 1125, ISSN: 0005470941 *
癌と化学療法, vol. 45, no. 10, JPN6024017217, 2018, pages 1498 - 1500, ISSN: 0005470942 *

Also Published As

Publication number Publication date
BR112021021663A2 (pt) 2022-05-17
CA3132656A1 (en) 2020-11-05
EP3962945A1 (en) 2022-03-09
KR20220002316A (ko) 2022-01-06
MX2021013271A (es) 2022-01-06
WO2020222668A1 (en) 2020-11-05
AU2020266083A1 (en) 2021-09-23
US20220195059A1 (en) 2022-06-23

Similar Documents

Publication Publication Date Title
JP6894952B2 (ja) 癌治療のためのｐｄ−１拮抗薬およびｖｅｇｆｒ阻害剤の組み合わせ
Vacchelli et al. Trial watch: Monoclonal antibodies in cancer therapy
JP7408396B2 (ja) 併用療法
US20220195059A1 (en) Rank Pathway Inhibitors in Combination with CDK Inhibitors
JP7054681B2 (ja) 組合せ療法
JP2022043060A (ja) 組み合わせ治療
JP2020517640A5 (enExample)
HK1252272A1 (zh) 使用抗ox40抗体治疗癌症的方法
JP7402691B2 (ja) 抗ｃｄ２５抗体薬物複合体による併用療法
JP2021522298A (ja) 癌治療のためのＰＤ−１／ＰＤ−Ｌ１、ＴＧＦβおよびＤＮＡ−ＰＫの同時阻害
JP2020517652A5 (enExample)
RS59738B1 (sr) Anti-ox40 antitela i postupci primene
KR20230059792A (ko) 암 치료를 위한 조합
CA2828075A1 (en) Use of inhibitors of egfr-family receptors in the treatment of hormone refractory breast cancers
Rosemblit et al. Oncodriver inhibition and CD4+ Th1 cytokines cooperate through Stat1 activation to induce tumor senescence and apoptosis in HER2+ and triple negative breast cancer: implications for combining immune and targeted therapies
WO2011069074A2 (en) Methods of treating metastatic breast cancer with trastuzumab-mcc-dm1
CA3084370A1 (en) Combination therapy with anti-il-8 antibodies and anti-pd-1 antibodies for treating cancer
JP2020517629A5 (enExample)
BR112019021472A2 (pt) Compostos de ligação ao amhrii para prevenção ou tratamento de cânceres
JP2020510673A (ja) がんの治療のための低分子ｃｓｆ−１ｒ阻害剤とｃｄ４０に特異的に結合するアゴニスト抗体とを含む併用療法
US10220091B2 (en) Combination treatments with sonic hedgehog inhibitors
JP2023501971A (ja) 癌の治療のための、放射線療法と共に用いるＰＤ－１、ＴＧＦβ、及びＡＴＭの組み合わせ阻害
CA2867700A1 (en) Potentiating antibody-induced complement-mediated cytotoxicity via pi3k inhibition
CA3180226A1 (en) Targeting abcb5 in glioblastoma multiforme
US20240279338A1 (en) Combination Treatment of Cancer

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230421

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20230421

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20240507

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20241127